Giovanni Porta

Prof. Dr. Giovanni Porta


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1998 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ACAlison J. Coffey
Alison J. Coffey
RBRobert A. Brooksbank
Robert A. Brooksbank
OBOliver Brandau
Oliver Brandau
TOToshitaka Oohashi
Toshitaka Oohashi
GHGareth R. Howell
Gareth R. Howell
DBDavid R. Bentley
David R. Bentley

21 March 2013 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PTPaola Tucci
Paola Tucci
GPGiovanni Porta
Giovanni Porta
MAMassimiliano Agostini
Massimiliano Agostini
DDD Dinsdale
D Dinsdale
Ivo IavicoliIvo Iavicoli
Ivo Iavicoli
AWA Willis
A Willis
The long-term health risks of nanoparticles remain poorly understood, which is a serious concern given their prevalence in the environment from increased industrial and domestic use. The extent to which such compounds contribute to cellular toxicity is unclear, and although it is known that induction of oxidative stress pathways is associated with this process, the proteins and the metabolic pathways involved with nanoparticle-mediated oxidative stress and toxicity are largely unknown. To investigate this problem further, the effect of TiO2 on the HaCaT human keratinocyte cell line was examined. The data show that although TiO2 does not affect cell cycle phase distribution, nor cell death, these nanoparticles have a considerable and rapid effect on mitochondrial function. Metabolic analysis was performed to identify 268 metabolites of the specific pathways involved and 85 biochemical metabolites were found to be significantly altered, many of which are known to be associated with the cellular stress response. Importantly, the uptake of nanoparticles into the cultured cells was restricted to phagosomes, TiO2 nanoparticles did not enter into the nucleus or any other cytoplasmic organelle. No other morphological changes were detected after 24-h exposure consistent with a specific role of mitochondria in this response.

4 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SDSimone Donati
Simone Donati
SCSimona Maria Caprani
Simona Maria Caprani
GAGiulia Airaghi
Giulia Airaghi
Riccardo VinciguerraRiccardo Vinciguerra
Riccardo Vinciguerra
LBLuigi Bartalena
Luigi Bartalena
CAClaudio Azzolini
Claudio Azzolini
Vitreoretinal surgery has advanced in numerous directions during recent years. The removal of the vitreous body is one of the main characteristics of this surgical procedure. Several molecules have been tested in the past to fill the vitreous cavity and to mimic its functions. We here review the currently available vitreous substitutes, focusing on their molecular properties and functions, together with their adverse effects. Afterwards we describe the characteristics of the ideal vitreous substitute. The challenges facing every ophthalmology researcher are to reach a long-term intraocular permanence of vitreous substitute with total inertness of the molecule injected and the control of inflammatory reactions. We report new polymers with gelification characteristics and smart hydrogels representing the future of vitreoretinal surgery. Finally, we describe the current studies on vitreous regeneration and cell cultures to create new intraocular gels with optimal biocompatibility and rheological properties.

15 March 2005 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Silvia SirchiaSilvia Sirchia
Silvia Sirchia
LRLisetta Ramoscelli
Lisetta Ramoscelli
FGFrancesca R. Grati
Francesca R. Grati
FBFloriana Barbera
Floriana Barbera
DCDanila Coradini
Danila Coradini
MMMonica Miozzo
Monica Miozzo
In females, X chromosome inactivation (XCI) begins with the expression of the XIST gene from the X chromosome destined to be inactivated (Xi) and the coating of XIST RNA in cis. It has recently been reported that this process is supported by the product of the BRCA1 tumor suppressor gene and that BRCA1−/− cancers show Xi chromatin structure defects, thus suggesting a role of XCI perturbation in BRCA1-mediated tumorigenesis. Using a combined genetic and epigenetic approach, we verified the occurrence of XCI in BRCA1−/− and BRCA1wt breast cancer cell lines. It was ascertained that the Xi was lost in all cancer cell lines, irrespective of the BRCA1 status and that more than one active X (Xa) was present. In addition, no epigenetic silencing of genes normally subjected to XCI was observed. We also evaluated XIST expression and found that XIST may be occasionally transcribed also from Xa. Moreover, in one of the BRCA1wt cell line the restoring of XIST expression using a histone deacetylase inhibitor, did not lead to XCI. To verify these findings in primary tumors, chromosome X behavior was investigated in a few BRCA1-associated and BRCA1–not associated primary noncultured breast carcinomas and the results mirrored those obtained in cancer cell lines. Our findings indicate that the lack of XCI may be a frequent phenomenon in breast tumorigenesis, which occurs independently of BRCA1 status and XIST expression and is due to the loss of Xi and replication of Xa and not to the reactivation of the native Xi.

15 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Silvia SirchiaSilvia Sirchia
Silvia Sirchia
STSilvia Maria Tabano
Silvia Maria Tabano
LMLaura Monti
Laura Monti
MRMaria P. Recalcati
Maria P. Recalcati
MGmanuela gariboldi
manuela gariboldi
MMMonica Miozzo
Monica Miozzo
A role of X chromosome inactivation process in the development of breast cancer have been suggested. In particular, the relationship between the breast cancer predisposing gene BRCA1 and XIST, the main mediator of X chromosome inactivation, has been intensely investigated, but still remains controversial. We investigated this topic by assessing XIST behaviour in different groups of breast carcinomas and in a panel of breast cancer cell lines both BRCA1 mutant and wild type. In addition, we evaluated the occurrence of broader defects of heterochromatin in relation to BRCA1 status in breast cancer cells. We provide evidence that in breast cancer cells BRCA1 is involved in XIST regulation on the active X chromosome, but not in its localization as previously suggested, and that XIST can be unusually expressed by an active X and can decorate it. This indicates that the detection of XIST cloud in cancer cell is not synonymous of the presence of an inactive X chromosome. Moreover, we show that global heterochromatin defects observed in breast tumor cells are independent of BRCA1 status. Our observations sheds light on a possible previously uncharacterized mechanism of breast carcinogenesis mediated by XIST misbehaviour, particularly in BRCA1-related cancers. Moreover, the significant higher levels of XIST-RNA detected in BRCA1-associated respect to sporadic basal-like cancers, opens the possibility to use XIST expression as a marker to discriminate between the two groups of tumors.

1 December 1991 in Genomics
Verified
Journal Article
Closed access
DSDavid Schlessinger
David Schlessinger
RLRandy D. Little
Randy D. Little
DFDiha Freije
Diha Freije
FAFatima Abidi
Fatima Abidi
IZIleana Zucchi
Ileana Zucchi
MDMichele D'Urso
Michele D'Urso